Anti-angiogenesis for cancer revisited: Is there a role for combinations with immunotherapy?

Rakesh R. Ramjiawan(Harvard University), Dan G. Duda(Massachusetts General Hospital)

Angiogenesis

March 30, 2017

10.1007/s10456-017-9552-y

Cited by 690

Related Papers

CXCR4 inhibition in tumor microenvironment facilitates anti‐programmed death receptor‐1 immunotherapy in sorafenib‐treated hepatocellular carcinoma in mice

|Hepatology|2014|456

Dual Programmed Death Receptor‐1 and Vascular Endothelial Growth Factor Receptor‐2 Blockade Promotes Vascular Normalization and Enhances Antitumor Immune Responses in Hepatocellular Carcinoma

|Hepatology|2019|404

Regorafenib combined with PD1 blockade increases CD8 T-cell infiltration by inducing CXCL10 expression in hepatocellular carcinoma

|Journal for ImmunoTherapy of Cancer|2020|149